| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5457126 | NOVARTIS | Use of lodoxamide to treat ophthalmic allergic conditions |
Oct, 2012
(11 years ago) | |
Alomide is owned by Novartis.
Alomide contains Lodoxamide Tromethamine.
Alomide has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Alomide are:
- US5457126
Alomide was authorised for market use on 23 September, 1993.
Alomide is available in solution/drops;ophthalmic dosage forms.
Alomide can be used as treatment of ocular allergic response in human eyes.
The generics of Alomide are possible to be released after 10 October, 2012.
Drugs and Companies using LODOXAMIDE TROMETHAMINE ingredient
Market Authorisation Date: 23 September, 1993
Treatment: Treatment of ocular allergic response in human eyes
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
ALOMIDE family patents
